Check out our latest news
TGA approves a new medication for MS: ofatumumab
Ofatumumab (Kesimpta®) approved by The Therapeutic Goods Administration (TGA) of Australia as a new treatment for relapsing forms of MS.
MSWA is WA’s leading contributor to neurological research
MSWA is proud to be Western Australia’s leading contributor to neurological research. This year, we are delighted to announce a new record contribution of $4m.
CORONAVIRUS (COVID-19)
MSWA is taking precautionary measures to protect the health and wellbeing of our community during the COVID-19 (coronavirus) outbreak.